{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:33Z","timestamp":1791327333461,"version":"4.3.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>It has been reported in prospective randomized trials that antithymocyte globulin (ATG)\u2013based graft-versus-host disease (GVHD) prophylaxis has benefits in the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with unrelated donors (UDs). However, the optimal GVHD prophylaxis strategy has been challenged recently by the increasing use of posttransplant cyclophosphamide (PTCY). We report from the European Society for Blood and Marrow Transplantation registry the outcomes of 960 patients with myelodysplastic neoplasms who underwent allo-HSCT from UD with PTCY or ATG as GVHD prophylaxis. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The disease characteristics were similar in both groups. Day 28 neutrophil engraftment was significantly better with ATG (93% vs 85%). Over a median follow-up of 4.4 years, the 5-year OS was 58% with PTCY, and 49% in the ATG group. The 5-year PFS was higher for PTCY at 53% vs 44% for ATG. Grade 2 to 4 acute GVHD incidence was lower when PTCY was used (23%), whereas there was no difference in the incidence of chronic GVHD at 5 years. Multivariable analyses confirmed better OS and PFS with PTCY with a hazard ratio (HR) for ATG of 1.32 (1-1.74) and a better PFS for PTCY with a HR for ATG of 1.33. This study suggests that GVHD prophylaxis using PTCY instead of ATG in this setting remains a valid option. Further prospective randomized studies would be essential to confirm these results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013468","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T19:23:58Z","timestamp":1721071438000},"page":"4792-4802","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-8104","authenticated-orcid":false,"given":"Yves","family":"Chalandon","sequence":"first","affiliation":[{"name":"1H\u00f4pitaux Universitaires de Gen\u00e8ve and Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diderik-Jan","family":"Eikema","sequence":"additional","affiliation":[{"name":"2EBMT Leiden Statistical Unit, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-0114","authenticated-orcid":false,"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[{"name":"3RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[{"name":"4Ospedale San Raffaele s.r.l., Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Koster","sequence":"additional","affiliation":[{"name":"5EBMT Leiden Study Unit, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[{"name":"6Institute of Hematology and Blood Transfusion, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"7University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[{"name":"8Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulay","family":"Ozcelik","sequence":"additional","affiliation":[{"name":"9Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-5378","authenticated-orcid":false,"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[{"name":"10Oslo University Hospital, Rikshospitalet Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"11University Hospital Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[{"name":"12King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[{"name":"13CHU de Lille, Univ Lille, INSERM U1286, INFINITE 59000, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"14Department of Oncology and Hematology, University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5844-1632","authenticated-orcid":false,"given":"Maija","family":"It\u00e4l\u00e4-Remes","sequence":"additional","affiliation":[{"name":"15Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[{"name":"16Fundeni Clinical Institute, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"17Hematology and BMT Unit, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[{"name":"18Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6539-226X","authenticated-orcid":false,"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"19University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Drozd-Sokolowska","sequence":"additional","affiliation":[{"name":"20University Clinical Centre, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-354X","authenticated-orcid":false,"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[{"name":"21University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[{"name":"21University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[{"name":"22H\u00f4pital Saint-Louis, APHP, Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"7","key":"2024092411560600400_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2024092411560600400_bib2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"2024092411560600400_bib3","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024092411560600400_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on practice guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"2024092411560600400_bib5","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2024092411560600400_bib6","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2024092411560600400_bib7","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024092411560600400_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024092411560600400_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024092411560600400_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"25","key":"2024092411560600400_bib11","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024092411560600400_bib12","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Prevention of graft versus host disease with hematopoietic cell transplantation with reduced intensity conditioning\u2014a comparison of three prophylaxis regimens (tacrolimus\/mycophenolate mofetil\/cyclophosphamide, tacrolimus\/methotrexate\/bortezomib or tacrolimus\/methotrexate\/maraviroc) versus tacrolimus\/methotrexate: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"2024092411560600400_bib13","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2024092411560600400_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024092411560600400_bib15","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024092411560600400_bib16","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.jtct.2022.12.017","article-title":"Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2024092411560600400_bib17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024092411560600400_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors","volume":"13","author":"Brissot","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024092411560600400_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"2024092411560600400_bib20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41409-018-0367-2","article-title":"Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10\/10 HLA-matched unrelated donor hematopoietic stem cell transplantation","volume":"54","author":"Shah","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024092411560600400_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.19031","article-title":"ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning","volume":"203","author":"Aydin","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"2024092411560600400_bib22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024092411560600400_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024092411560600400_bib24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1083-8791(03)00162-9","article-title":"Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review","volume":"9","author":"Weisdorf","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024092411560600400_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024092411560600400_bib26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2024092411560600400_bib27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation","volume":"48","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024092411560600400_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ajh.27195","article-title":"Individualized rabbit anti-thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high-risk hematologic malignancy: exposure-response analysis and population pharmacokinetics simulations","volume":"99","author":"Teramoto","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2024092411560600400_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"2024092411560600400_bib30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024092411560600400_bib31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtct.2021.06.018","article-title":"Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome","volume":"27","author":"Modi","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024092411560600400_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","article-title":"Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"127","author":"Battipaglia","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"2024092411560600400_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-020-04317-7","article-title":"Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation","volume":"100","author":"Bail\u00e9n","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"2024092411560600400_bib34","doi-asserted-by":"crossref","first-page":"695.e1","DOI":"10.1016\/j.jtct.2022.07.021","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"2024092411560600400_bib35","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/bloodadvances.2022007596","article-title":"Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant","volume":"6","author":"Jimenez","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2024092411560600400_bib36","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1002\/cncr.35004","article-title":"Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"129","author":"Giebel","year":"2023","journal-title":"Cancer"},{"issue":"34","key":"2024092411560600400_bib37","doi-asserted-by":"crossref","first-page":"e21571","DOI":"10.1097\/MD.0000000000021571","article-title":"A\u00a0comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation","volume":"99","author":"Lee","year":"2020","journal-title":"Medicine (Baltim)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4792\/2243792\/blooda_adv-2024-013468-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4792\/2243792\/blooda_adv-2024-013468-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:46:44Z","timestamp":1727185604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4792\/517033\/Unrelated-donor-transplantation-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":37,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013468","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}